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PPN5
COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINED
ORAL TREATMENT WITH TRAMADOL/ACETAMINOPHEN
(TRAMACET®) FOR THE MANAGEMENT OF LOWER 
BACK PAIN AT THE IMSS (MEXICAN INSTITUTE OF 
SOCIAL SECURITY)
Vazquez V1, Sumano I2
1Janssen-Cilag, Mexico, Mexico, Mexico, 2Janssen Cilag, Ciudad De
México, México D. F, Mexico
OBJECTIVES: To assess the cost-effectiveness of a ﬁxed combi-
nation of Tramadol and Acetaminophen (Tramacet*) for the
management of Lower Back Pain (LBP) in Mexico. The eco-
nomic evaluation was performed from a Mexican Institute of
Social Security (IMSS), health service hospital perspective.
METHODS: A cost-effectiveness analysis was developed with a
decision model. The cost-effectiveness ratio for the therapeutic
use of the ﬁxed combination of Tramadol and acetaminophen
(Tramacet*) compared to treatment with Piroxicam, Celecoxib
and Diclofenac was estimated. One thousand of patients hospi-
talized in 2004 at the IMSS with LBP crisss were retrospectively
included. This sample was used as a pattern for analyzing each
alternative. A decision tree was developed based on the treat-
ment of the disorder within the national health care system, and
the cost for each node was determined. The costs of drug therapy,
family medicine ambulatory consultations, clinical specialty con-
sultations, rehabilitation, emergency care and hospitalization
were included. Labor productivity and disability rates were also
considered. Costs sources were obtained from the ofﬁcial and
published ﬁnancial and costs reports of IMSS. RESULTS: Tra-
macet leads to an increase in the number of patients with posi-
tive response to the treatment. Therapy with Tramacet had an
annual cost of $28,640 pesos (2603.63 USD), and had the lowest
hospitalization cost of all the alternatives. Also, Tramacet leads
to savings for $2769 pesos (251.72 USD), compared to conven-
tional treatment, and $648 pesos (58.90 USD) compared to
Piroxicam; additionally, for every percentage point of increased
improvement in the quality of life, Tramacet leads to savings of
$374 pesos(34 USD). CONCLUSION: This study demonstrated
that Tramacet is a cost-efﬁcient and dominant alternative for the
management of patients with chronic to acute LBP.
PPN6
A COST MINIMIZATION ANALYSIS OF IV BOLUS VERSUS IV
INFUSION DICLOFENAC IN POST-OPERATIVE PAIN
Wallerstein K
PharmaFocus LLC, Belle Mead, NJ, USA
OBJECTIVES: There are two forms of injectable IV diclofenac
available (bolus and infusion). We conducted a cost minimiza-
tion analysis to determine the total cost of each treatment strat-
egy. METHODS: A decision-analytic model was developed to
estimate total treatment costs of IV bolus versus IV infusion
diclofenac. The modeled population was patients who post-
operatively would require injectable NSAIDs to control their
pain. The model timeframe was for the duration that a patient
required post-operative pain management with injectable med-
ication. The model inputs included the cost of medicines
(NSAIDs and rescue medication), the cost of the IV administra-
tion process (staff time and consumables), and the cost of treat-
ing adverse events (staff time, medicines and consumables). The
unit costs and resources are based on UK data. The results are
expressed as Pounds Sterling and as average cost per patient.
One-way sensitivity analyses were also conducted on key para-
meters. RESULTS: The total cost of treating post-operative pain
was less with IV bolus diclofenac than with IV infusion
diclofenac. Diclofenac IV bolus cost a mean GPB26.72 per
patient overall versus diclofenac IV infusion mean cost of
GPB77.18 per patient. The difference in overall cost is attribut-
able to the cost of NSAIDs (IV bolus GPB11.43 versus GPB1.69
IV Infusion), the cost of administering the NSAIDs (IV bolus
GPB9.00 versus GPB48.28 IV Infusion) and the cost of con-
sumables (IV bolus GPB1.38 versus GPB16.70 IV infusion). The
difference in the costs of rescue medication (IV bolus GPB2.80
versus GPB6.14 IV infusion) and of treating adverse events (IV
bolus GPB2.11 versus GPB4.37 IV infusion) was less. One-way
sensitivity analyses show the results are sensitive to the cost of
staff time and consumables. CONCLUSION: Diclofenac IV
bolus is cost saving relative to diclofenac IV infusion in the treat-
ment of post-operative pain.
PPN7
THE SPECTRUM OF HEALTH CARE COSTS ASSOCIATED
WITH HERPES ZOSTER:ACUTE PAIN VS.
POSTHERPETIC NEURALGIA
Hawkins K1,White R2, Dworkin R3, O’connor A3, Baser O4
1IMS Health, Brooklyn, MI, USA, 2Endo Pharmaceuticals, Chadds Ford,
PA, USA, 3University of Rochester School of Medicine and Dentistry,
Rochester, NY, USA, 4Medstat, Ann Arbor, MI, USA
OBJECTIVES: To estimate the burden of illness (BOI) of herpes
zoster (HZ) pain and postherpetic neuralgia (PHN) in a com-
mercially insured, Medicare, and Medicaid populations.
METHODS: Health care expenditures attributable to HZ acute
pain and postherpetic neuralgia (PHN) were calculated using
Thomson-Medstat’s databases for inpatient, outpatient, and out-
patient prescription claims. Patient cohorts were deﬁned as those
with a diagnosis of PHN, those with a diagnosis of HZ and less
than 30 days of analgesic use, and those with a diagnosis of HZ
and more then 30 days of analgesic use. For each of these
cohorts, a random sample of patients without HZ or PHN was
selected and propensity score matched based on patient demo-
graphics and overall comorbidities. Expenditures between
PHN/HZ cohorts and matched control cohorts were compared
to derive the BOI attributable to each condition. This was done
separately for commercially insured, Medicaid, and Medicare
patients. RESULTS: Patients without a diagnosis of PHN were
much more common in the sample than were patients diagnosed
with PHN. The average cost per patient in the year following a
diagnosis of HZ and less than 30 days of analgesic use ranged
from $757 to $1313, depending on type of insurance. The
average cost associated with a diagnosis of PHN or with a diag-
nosis of HZ followed by greater than 30 days of analgesic use
but no diagnosis of PHN were similar and ranged from $2159
to $5742. CONCLUSION: Health care costs associated with
PHN were substantially greater than those associated with HZ
pain that resolved within 30 days. Because patients with a diag-
nosis of HZ and persisting analgesic use (but no diagnosis of
PHN) accounted for the majority of the total expenditures,
future research must consider the impact of under-diagnosis on
estimates of the health costs associated with both HZ and PHN.
PPN8
OUT-OF-POCKET PRICES OF OPIOID ANALGESICS IN THE
UNITED STATES
Craig BM1, Strassels SA2
1University of Wisconsin, Madison, WI, USA, 2University of Texas at
Austin College of Pharmacy, Austin,TX, USA
OBJECTIVES: Pain is one of the most common reasons that
patients seek medical care, yet little information is available
about the out-of-pocket costs of pain management. Economic
burden is of particular interest in the United States, because drug
prices are allowed to ﬂuctuate freely across time, region, and
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system, which can lead to disparities in treatment. METHODS:
Using nationally representative data from the Medicare Current
Beneﬁciary Survey, 1992–2003 and the Medical Expenditure
Panel Survey, 1999–2003, we estimated the out-of-pocket prices
for common opioid analgesics among community-dwelling
adults in theUnited States. Standardized gamma mixture models
were estimated to predict out-of-pocket prices for individuals
with and without drug coverage controlling for setting charac-
teristics, such as year, as well as prescription speciﬁc attributes
such as number of tablets and controlled release form.
RESULTS: Typical prescription for opioid analgesics costs a
patient between $6.20 and $64.17, if they have drug coverage,
and between $16.22 and 134.60 without coverage. CONCLU-
SION: A better understanding of the endogeneity of out-of-
pocket prices not only improves our ability to identify the
demand for health care, these models better characterize the
ﬁnancial burden of pain management.
PPN9
COSTS AND COMORBIDITIES IN LOWER BACK PAIN
PATIENTS USING NARCOTIC MEDICATIONS
Rhee Y1, Taitel MS2
1Northwestern University, Chicago, IL, USA, 2Matria Health care,
Rosemont, IL, USA
OBJECTIVES: To identify lower back pain (LBP) patients who
use narcotic medications and examine their medication behav-
iors, medical and pharmacy claim costs and associated comor-
bidities. METHODS: This study used medical and pharmacy
claims data from 165,569 employees’ ages 18 to 64 years from
three employer groups from September 2002 to December 2003.
LBP patients were identiﬁed using ICD-9 diagnosis codes from
medical claims data. Differences in costs and comorbidities were
examined between LBP patients who use narcotic medications
and LBP patients who do not use narcotic medications.
RESULTS: Among eligible members, 13,760 (8.3%) were iden-
tiﬁed as LBP patients. Nearly 60% were female with an average
age of 46.8 years. Approximately half of the LBP patients
(44.8%) used narcotic medications; however, they consumed
71% of total health care costs (medical plus pharmacy costs)
among LBP patients. The average monthly total health care cost
for a narcotic-using LBP patient was $1,040 versus $347 for a
LBP patient without narcotics. Narcotic-using LBP patients had
signiﬁcantly (p < 0.001) higher rates of comorbid conditions than
LBP patients without narcotic use: hypertension (22.9% vs.
13.3%), arthritis (14.1% vs. 4.3%), diabetes (10.4% vs. 5.6%),
asthma (7.4% vs. 4.0%), coronary artery disease (5.0% vs.
2.5%), depression (10.3% vs. 5.4%) and anxiety (6.3% vs.
2.8%). Also, LBP patients with comorbid anxiety or depression
on average used more narcotic medications than patients with
other comorbidities. LBP patients who use narcotic medications
are also more likely to visit the emergency room, use physical
therapy or chiropractic services, utilize one or more epidurals
and/or MRI’s, or have a surgery (p < 0.001). CONCLUSION:
Lower back pain patients who use narcotic medications are more
likely to have additional health conditions and higher health care
costs than non-narcotic using LBP patients. Further, patients
with comorbid anxiety or depression take more narcotics than
those with other comorbidities.
PPN10
COSTS ATTRIBUTABLE TO INTRAVENOUS PATIENT
CONTROLLED ANALGESIA: FOCUS ON 
DEVICE-RELATED EVENTS
Nelson WW1, Meissner BL1, Gagne JJ2, Schein JR3
1Xcenda, Palm Harbor, FL, USA, 2Thomas Jefferson University,
Philadelphia, PA, USA, 3Ortho-McNeil Janssen Scientiﬁc Affairs, LLC,
Raritan, NJ, USA
OBJECTIVES: To estimate the costs of device-related events
associated with intravenous patient-controlled analgesia (IV
PCA) from the perspective of a hospital or integrated health-
system. METHODS: To estimate the costs attributable to both
harmful and non-harmful IV PCA device-related events, a quasi-
cost accounting methodology is utilized. Data were obtained
from the Manufacturer and User facility Device Experience
(MAUDE) dataset, published literature, and expert opinions.
The MAUDE dataset is publicly available, and contains manda-
tory FDA reports of medical device-related events. IV PCA event
reports were identiﬁed from the MAUDE database (January 1,
2002-December 31, 2003) and the descriptive text was qualita-
tively reviewed to collect data on event consequences. The level
of care rendered for the event consequences was estimated by
applying clinical assumptions validated by an expert advisory
panel. Both variable and opportunity costs (2006 values) were
considered, including medication, laboratory, lost revenue, and
labor. Whenever an event consequence was indicated in a report,
the corresponding costs were applied to derive the estimated
mean cost for each event type. The event types were previously
deﬁned and published (Device Safety Events, Operator Errors,
Adverse Reactions to Opioids, Patient-related Events, and Inde-
terminate Events). RESULTS: The most costly event type was
Adverse Reactions to Opioids, followed by Operator Errors
(mean costs of $13,803 and $2,955 respectively). When strati-
ﬁed, events reported to be harmful to patients were associated
with higher costs than non-harmful events: $3483 vs. $0 for
Device Safety Events, $5756 vs. $361 for Operator Errors, $199
vs. $11 for Patient-related Events, and $6120 vs. $142 for Inde-
terminate Events; by deﬁnition, Adverse Reactions to Opioids
were all harmful events. CONCLUSION: IV PCA device-related
events are costly to hospitals due to their association with patient
care consequence. This study provides an innovative approach
to estimating the cost of device-related events. Additional
research is necessary to validate these ﬁndings.
PPN11
COSTS OF ERRORS ATTRIBUTABLE TO INTRAVENOUS
PATIENT CONTROLLED ANALGESIA—FOCUS ON
MEDICATION-RELATED ERRORS
Meissner BL1, Hicks RW2, Schein JR3, Sikirica V3
1Xcenda, Palm Harbor, FL, USA, 2U S Pharmacopeia, Rockville, MD,
USA, 3Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Raritan, NJ, USA
OBJECTIVES: The objective of this study was to estimate the
frequency and cost of medication errors associated with intra-
venous patient-controlled analgesia (IV PCA) from the perspec-
tive of a hospital or integrated health-system. METHODS: This
study utilized a quasi-cost accounting methodology to estimate
the costs attributable to both harmful and non-harmful IV PCA
errors. Data for the study were obtained from the MEDMARX®
dataset, published literature, and expert opinions. MEDMARX
is an anonymous error-reporting database maintained by the
United States Pharmacopeia. The database accepts multiple
inputs of error causes and error consequences per event (i.e.,
error cause and consequence categories not mutually exclusive).
The level of care rendered was estimated by applying clinical
assumptions (validated by an expert advisory panel) to each 
